You are here

Krazati

BMS Pulls Ahead of Amgen, Aces Confirmatory Phase III NSCLC Trial for Krazati

BioSpace

Mon, 04/1/24 - 11:59 am

Bristol Myers Squibb

clinical trials

non-small cell lung cancer

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

CP Wire/Businesswire

Sun, 10/8/23 - 06:16 pm

Bristol Myers Squibb

Mirati Therapeutics

Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients

Clinical Trials Arena

Mon, 09/11/23 - 12:29 pm

Mirati Therapeutics

non-small cell lung cancer

clinical trials

Mirati's flagship KRAS inhibitor Krazati gets rebuffed in Europe

Fierce Pharma

Sun, 07/23/23 - 12:38 pm

Mirati Therapeutics

Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear

Fierce Pharma

Thu, 05/11/23 - 09:07 pm

Mirati Therapeutics

FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen

MedCity News

Wed, 12/14/22 - 10:19 am

Mirati Therapeutics